MT
Therapeutic Areas
Mineralys Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lorundrostat (MLS-101) | Treatment-Resistant Hypertension (TRH) | Phase 2 |
Leadership Team at Mineralys Therapeutics
JC
Jon Congleton
Chief Executive Officer
DR
David Rodman
Chief Medical Officer
AL
Adam Levy
Chief Financial Officer
EW
Eric Warren
Chief Commercial Officer
JI
Jessica Ibbitson
Executive Vice President, Operations
RM
Robert McKean
Senior Vice President, CMC
DM
Danielle Mahoney
Senior Vice President, Quality Assurance
JB
Jose Breton
Senior Vice President, Finance & Controller
TB
Tiffany Burt
Senior Vice President, Medical Affairs
SF
Sarah Foster
Senior Vice President, People